Comparison of tau-PET tracers: Progress towards a universal measure

tau-PET 示踪剂的比较：通用测量的进展

• 批准号: 10169910
• 负责人: Oscar L. Lopez
• 金额: $ 24.49万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2021-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10169910
• 关键词: Address; Adult; Aging; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Area; Behavioral Symptoms; Binding; Biological; Biological Markers; Biology; Brain; Brain imaging; Characteristics; Classification; Clinical; Clinical Data; Clinical assessments; Cognition; Cognition Disorders; Communication; Communities; Data; Data Collection; Data Set; Databases; Dementia; Deposition; Development; Diagnostic Imaging; Early Diagnosis; Early treatment; Enrollment; Environment; Epidemiology; Etiology; Evolution; Faculty; Family; Foundations; Functional disorder; Genetic; Genetic study; Goals; Guanosine Triphosphate; Human; Human Resources; Image; Imaging Device; Imaging Techniques; Imaging ligands; Individual; Institution; International; Investments; Lead; Ligands; Magnetic Resonance Imaging; Masks; Measures; Methodology; Methods; Monitor; Natural History; Neurobehavioral Manifestations; Outcome; Participant; Pathogenesis; Pathologic; Pathologic Processes; Patients; Performance; Positioning Attribute; Positron-Emission Tomography; Procedures; Protein Isoforms; Psychotic Disorders; Public Health; Recording of previous events; Reporting; Research; Research Personnel; Sampling; Sampling Studies; Scoring Method; Solid; Standardization; Structure; Structure of choroid plexus; Symptoms; Techniques; Technology; Testing; Tracer; Training Programs; Translational Research; Treatment Efficacy; Universities; Validation; Work; amyloid imaging; career; clinical biomarkers; clinical effect; cohort; comorbidity; demented; design; effective therapy; eligible participant; gray matter; head-to-head comparison; health care delivery; imaging agent; improved; insight; interdisciplinary approach; multidisciplinary; neuroimaging; neuropathology; neuropsychiatry; non-demented; novel; novel therapeutics; pre-clinical; programs; psychogenetics; radiotracer; ranpirnase; structured data; tau Proteins; tau aggregation; white matter

Overall: Summary/Abstract: The University of Pittsburgh Alzheimer’s Disease Research Center (PITT- ADRC) has shown a clear scientific evolution over the past three decades. Since our inception, we have advanced the areas of AD neuropsychiatry, genetics, natural history of AD, validation of clinical criteria, and clinico-pathological correlations, and have pioneered the development of PET amyloid tracers, which have transformed AD research. We have used a multidisciplinary approach to better understand the transition from normal cognition to dementia, have explored the biology of more aggressive forms of AD characterized by psychosis, and have made and contributed to new insights in genetics. This solid scientific background and investment in junior investigators has allowed the PITT-ADRC to develop areas of excellence, which form the foundation of our Center going forward. These are reflected in the Center’s cores, and most notably in the large number of studies we support in these areas in Pittsburgh and at national and international level. The PITT-ADRC is committed to remain at the forefront of the scientific efforts to understand the pathological processes involved in the etiology of AD. Along with the high level of research conducted by the PITT-ADRC, we are also dedicated to developing strong training programs to promote the careers of young investigators, consolidate the career of midlevel investigators, and to create strong ties with the community through educational and support programs. The PITT-ADRC is highly committed to leverage the strengths of the network of Centers to provide large numbers of samples and standardized clinical data collection from our participants. The PITT-ADRC has designed novel methodology that improves the accessibility of its database to local and national researchers, and it has been a key player in multiple studies that advanced the understanding of AD pathology and its possible implications for the development of novel treatments and other symptoms. Therefore, we provide an excellent environment that enhances cutting-edge research by bringing together a multidisciplinary team of investigators to study AD and other dementias, and to improve health care delivery. The methodology proposed in this application will lead us to the creation of a unique and well-characterized cohort of patients and normal control subjects assessed with state of the art clinical and biomarker methods. This will allow us to test multiple scientific hypotheses and to examine the short- and long-term public health outcomes of the pathophysiology of cognitive disorders in the adult. We believe that the PITT -ADRC will be at the center of the new era of AD research that will require a wealth of clinical and biological data, highly sophisticated biomarker methodologies, close inter-relationship among centers and institutions, creation and optimization of human resources, and enhanced communication with patients and families.

总体：总结/摘要： 匹兹堡大学阿尔茨海默病研究中心（PITT- ADRC）在过去的三十年里显示了明显的科学发展。自成立以来，我们 推进了AD神经精神病学、遗传学、AD自然史、临床标准验证等领域， 临床病理相关性，并率先开发PET淀粉样蛋白示踪剂， 改变了AD研究。我们使用了多学科的方法来更好地理解从 对痴呆症的正常认知，探索了更具侵略性的AD形式的生物学特征， 精神病，并作出了贡献，在遗传学的新见解。这种坚实的科学背景和 对初级调查人员的投资使PITT-ADRC能够发展卓越领域，这些领域构成了 我们中心的基础向前发展。这些都反映在该中心的核心，最显着的是在 我们在匹兹堡以及国家和国际层面支持这些领域的大量研究。 PITT-ADRC致力于保持在科学努力的最前沿，以了解 AD病因学中涉及的病理过程。沿着高水平的研究， PITT-ADRC，我们还致力于开发强大的培训计划，以促进年轻人的职业生涯 调查员，巩固中级调查员的职业生涯，并与社区建立牢固的联系 通过教育和支持计划。 PITT-ADRC高度致力于利用中心网络的优势， 样本数量和标准化的临床数据收集从我们的参与者。PITT ADRC 设计了一种新的方法，提高了当地和国家研究人员对其数据库的访问能力， 它一直是多项研究的关键参与者，这些研究促进了对AD病理学及其 对开发新的治疗方法和其他症状的可能影响。因此，我们提供一个 优秀的环境，通过汇集多学科团队， 研究人员研究AD和其他痴呆症，并改善医疗服务。 在本申请中提出的方法将引导我们创建一个独特的和良好的特点， 用最新技术水平的临床和生物标志物方法评估的患者和正常对照受试者的队列。 这将使我们能够测试多个科学假设，并检查短期和长期的公共卫生 成人认知障碍的病理生理学结果。 我们相信，PITT-ADRC将在AD研究的新时代的中心，这将需要一个 丰富的临床和生物学数据、高度复杂的生物标志物方法、密切的相互关系 在中心和机构之间，创造和优化人力资源，加强交流 病人和家属。